MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Puma Biotechnology Inc

Closed

SectorHealthcare

3.39 1.19

Overview

Share price change

24h

Current

Min

3.32

Max

3.41

Key metrics

By Trading Economics

Income

-16M

3M

Sales

-13M

46M

P/E

Sector Avg

4.423

39.857

Profit margin

6.464

Employees

172

EBITDA

-14M

4M

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

-12.79% downside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

12M

171M

Previous open

2.2

Previous close

3.39

News Sentiment

By Acuity

16%

84%

25 / 376 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lip 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 lip 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 lip 2025, 21:04 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 lip 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 lip 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 lip 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 lip 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 lip 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 lip 2025, 22:43 UTC

Acquisitions, Mergers, Takeovers

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 lip 2025, 22:43 UTC

Acquisitions, Mergers, Takeovers

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 lip 2025, 22:40 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lip 2025, 22:40 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 lip 2025, 22:30 UTC

Market Talk
Earnings

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 lip 2025, 22:20 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

17 lip 2025, 22:20 UTC

Market Talk
Earnings

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 lip 2025, 22:04 UTC

Market Talk
Earnings

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 lip 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 lip 2025, 21:58 UTC

Market Talk
Earnings

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 lip 2025, 21:57 UTC

Earnings

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lip 2025, 21:47 UTC

Earnings

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 lip 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 lip 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 lip 2025, 21:38 UTC

Acquisitions, Mergers, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 lip 2025, 21:22 UTC

Acquisitions, Mergers, Takeovers

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lip 2025, 21:05 UTC

Earnings

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 lip 2025, 21:04 UTC

Acquisitions, Mergers, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 lip 2025, 21:02 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 lip 2025, 20:59 UTC

Acquisitions, Mergers, Takeovers

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 lip 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

17 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-12.79% downside

12 Months Forecast

Average 3 USD  -12.79%

High 4 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

0

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

25 / 376 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.